首页 > 最新文献

BMJ Surgery Interventions Health Technologies最新文献

英文 中文
Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure. 前列腺活检技术对精准前列腺切除术结果的影响。
Q2 Medicine Pub Date : 2022-07-06 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000122
Ralph Grauer, Michael A Gorin, Akshay Sood, Mohit Butaney, Phil Olson, Guillaume Farah, Renee Hanna Cole, Wooju Jeong, Firas Abdollah, Mani Menon

Objective: To assess the impact of iterative changes in preoperative and postoperative biopsy techniques on the outcomes of men undergoing the precision prostatectomy procedure. Precision prostatectomy is a novel surgical treatment for prostate cancer that aims to maximally preserve erectogenic nerves via partial preservation of the prostate capsule.

Design: Retrospective.

Setting: Single tertiary care center.

Participants: This study included 120 patients who consented to undergo prostate cancer treatment with the precision prostatectomy procedure. Patients were originally enrolled in one of two separate prospective protocols studying precision prostatectomy.

Interventions: Preoperatively, 60 patients were screened with transrectal (TR) biopsy and 60 were screened by transperineal (TP) biopsy. Ultimately, 117 patients underwent precision prostatectomy. Of the 43 postoperative biopsies, 19 were TR; 17 were TP with ultrasound; and 7 were TP with microultrasound (mUS).

Main outcome measures: Preoperatively, we evaluated whether the transition to TP biopsy was associated with differences in postoperative treatment failure defined as a neoplasm-positive postoperative biopsy. Postoperative biopsies were compared with respect to their ability to sample the remnant tissue, specifically percentage of cores positive for prostate tissue.

Results: Preoperatively, 9/60 (15%) positive postoperative biopsies occurred in the TR group and 6/60 (10%) in the TP group; Kaplan-Meier survival estimates did not differ between groups (p=0.69 by log rank). Postoperatively, the numbers of cores positive for prostate tissue were 99/160 (62%), 63/107 (59%), and 36/39 (92%) in the TR biopsy, TP with ultrasound, and TP with mUS groups, respectively; this difference was statistically significant versus the rate in the TR and standard TP groups (p=0.0003 and 0.0002).

Conclusion: We found no significant improvement in patient screening, preoperatively-though limited by small sample size and relatively short follow-up. The incorporation of high-frequency mUS for postoperative biopsies improved the ability to sample the remnant tissue with a higher efficiency.

目的:评估术前和术后活检技术的反复变化对男性精密前列腺切除术结果的影响。精确前列腺切除术是一种新的前列腺癌手术治疗方法,旨在通过部分保存前列腺包膜来最大限度地保护勃起神经。设计:回顾性。环境:单一三级保健中心。参与者:本研究包括120名同意接受精确前列腺切除术治疗的前列腺癌患者。患者最初被纳入研究精确前列腺切除术的两个独立的前瞻性方案之一。干预措施:术前60例患者行经直肠活检(TR)筛查,60例行经会阴活检(TP)筛查。最终,117例患者接受了精准前列腺切除术。43例术后活检中,TR 19例;超声TP 17例;7例为超声TP (mUS)。主要结局指标:术前,我们评估了TP活检是否与术后治疗失败(肿瘤阳性术后活检)的差异有关。比较术后活检对残余组织取样的能力,特别是前列腺组织核阳性的百分比。结果:术前TR组术后活检阳性9/60 (15%),TP组术后活检阳性6/60 (10%);Kaplan-Meier生存估计在组间无差异(log rank p=0.69)。术后TR活检组、超声TP组、mUS组前列腺组织核阳性率分别为99/160(62%)、63/107(59%)、36/39 (92%);与TR组和标准TP组相比,这一差异具有统计学意义(p=0.0003和0.0002)。结论:我们发现术前患者筛查没有显著改善,尽管样本量小,随访时间相对较短。在术后活检中加入高频mUS提高了以更高效率对残余组织进行取样的能力。
{"title":"Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure.","authors":"Ralph Grauer,&nbsp;Michael A Gorin,&nbsp;Akshay Sood,&nbsp;Mohit Butaney,&nbsp;Phil Olson,&nbsp;Guillaume Farah,&nbsp;Renee Hanna Cole,&nbsp;Wooju Jeong,&nbsp;Firas Abdollah,&nbsp;Mani Menon","doi":"10.1136/bmjsit-2021-000122","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000122","url":null,"abstract":"<p><strong>Objective: </strong>To assess the impact of iterative changes in preoperative and postoperative biopsy techniques on the outcomes of men undergoing the precision prostatectomy procedure. Precision prostatectomy is a novel surgical treatment for prostate cancer that aims to maximally preserve erectogenic nerves via partial preservation of the prostate capsule.</p><p><strong>Design: </strong>Retrospective.</p><p><strong>Setting: </strong>Single tertiary care center.</p><p><strong>Participants: </strong>This study included 120 patients who consented to undergo prostate cancer treatment with the precision prostatectomy procedure. Patients were originally enrolled in one of two separate prospective protocols studying precision prostatectomy.</p><p><strong>Interventions: </strong>Preoperatively, 60 patients were screened with transrectal (TR) biopsy and 60 were screened by transperineal (TP) biopsy. Ultimately, 117 patients underwent precision prostatectomy. Of the 43 postoperative biopsies, 19 were TR; 17 were TP with ultrasound; and 7 were TP with microultrasound (mUS).</p><p><strong>Main outcome measures: </strong>Preoperatively, we evaluated whether the transition to TP biopsy was associated with differences in postoperative treatment failure defined as a neoplasm-positive postoperative biopsy. Postoperative biopsies were compared with respect to their ability to sample the remnant tissue, specifically percentage of cores positive for prostate tissue.</p><p><strong>Results: </strong>Preoperatively, 9/60 (15%) positive postoperative biopsies occurred in the TR group and 6/60 (10%) in the TP group; Kaplan-Meier survival estimates did not differ between groups (p=0.69 by log rank). Postoperatively, the numbers of cores positive for prostate tissue were 99/160 (62%), 63/107 (59%), and 36/39 (92%) in the TR biopsy, TP with ultrasound, and TP with mUS groups, respectively; this difference was statistically significant versus the rate in the TR and standard TP groups (p=0.0003 and 0.0002).</p><p><strong>Conclusion: </strong>We found no significant improvement in patient screening, preoperatively-though limited by small sample size and relatively short follow-up. The incorporation of high-frequency mUS for postoperative biopsies improved the ability to sample the remnant tissue with a higher efficiency.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/da/bmjsit-2021-000122.PMC9260793.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40548336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review and meta-analysis of Veress needle entry versus direct trocar entry in gynecologic surgery. 妇科手术中韦勒氏针入路与直接套管入路的系统回顾和荟萃分析。
IF 2.1 Q2 SURGERY Pub Date : 2022-06-28 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000121
Greg J Marchand, Ahmed Masoud, Alexa King, Giovanna Brazil, Hollie Ulibarri, Julia Parise, Amanda Arroyo, Catherine Coriell, Sydnee Goetz, Carmen Moir, Ashley Christensen, Tia Alexander, Malini Govindan

Objective: Although many studies have been performed, no consensus exists as to the ideal entry for laparoscopic gynecologic surgery. We sought out to compare the safety of direct trocar insertion with that of the Veress needle entry technique in gynecologic laparoscopic surgery.

Design: Systematic review with meta-analysis.

Setting: We searched Medline, ClinicalTrials.Gov, PubMed, Cochrane CENTRAL, SCOPUS, and Web of Science from their inception through 31 July 2021 for relevant studies. We included only controlled trials and ultimately seven trials were included in our meta-analysis.

Participants: Inclusion criteria included women undergoing gynecological laparoscopic surgery.

Intervention: The intervention of direct trocar insertion technique compared with Veress needle entry technique.

Main outcome measures: We compared five different outcomes associated with the efficacy and complications of laparoscopic entry.

Results: The pooled analysis showed that Veress needle entry was associated with a significant increase in the incidences of extraperitoneal insufflation (RR=0.177, 95% Cl (0.094 to 0.333), p<0.001), omental injury (RR=0.418, 95% Cl (0.195 to 0.896), p<0.001), failed entry (RR=0.173, 95% Cl (0.102 to 0.292), p<0.001), and trocar site infection (RR=0.404, 95% Cl (0.180 to 0.909), p<0.029). There was no significant difference between the two groups regarding the visceral injury (RR=0.562, 95% Cl (0.047 to 6.676), p<0.648).

Conclusions: When excluding all data apart from gynecologic surgery, the Veress needle entry technique may have an increased incidence of some, but not all complications of laparoscopic entry. It may also have a higher incidence of failed entry compared with direct entry techniques. Care should be taken in extrapolating these general results to specific surgeon experience levels.

Trial registration number: CRD42021273726.

目的:虽然已经进行了许多研究,但对于腹腔镜妇科手术的理想入路仍未达成共识。我们试图比较在妇科腹腔镜手术中直接套管插入与 Veress 针入路技术的安全性:设计:系统回顾与荟萃分析:我们检索了 Medline、ClinicalTrials.Gov、PubMed、Cochrane CENTRAL、SCOPUS 和 Web of Science 从开始到 2021 年 7 月 31 日的相关研究。我们只纳入了对照试验,最终有七项试验被纳入荟萃分析:纳入标准包括接受妇科腹腔镜手术的女性:主要结果测量指标:我们比较了与腹腔镜置入技术的疗效和并发症相关的五种不同结果:汇总分析显示,Veress针入路与腹膜外充气发生率的显著增加有关(RR=0.177,95% Cl(0.094至0.333),p结论:如果排除妇科手术以外的所有数据,Veress进针技术可能会增加腹腔镜进针的某些并发症的发生率,但不是所有并发症。与直接进针技术相比,它的进针失败率也可能更高。在将这些一般结果推断到特定外科医生的经验水平时应小心谨慎:试验注册号:CRD42021273726。
{"title":"Systematic review and meta-analysis of Veress needle entry versus direct trocar entry in gynecologic surgery.","authors":"Greg J Marchand, Ahmed Masoud, Alexa King, Giovanna Brazil, Hollie Ulibarri, Julia Parise, Amanda Arroyo, Catherine Coriell, Sydnee Goetz, Carmen Moir, Ashley Christensen, Tia Alexander, Malini Govindan","doi":"10.1136/bmjsit-2021-000121","DOIUrl":"10.1136/bmjsit-2021-000121","url":null,"abstract":"<p><strong>Objective: </strong>Although many studies have been performed, no consensus exists as to the ideal entry for laparoscopic gynecologic surgery. We sought out to compare the safety of direct trocar insertion with that of the Veress needle entry technique in gynecologic laparoscopic surgery.</p><p><strong>Design: </strong>Systematic review with meta-analysis.</p><p><strong>Setting: </strong>We searched Medline, ClinicalTrials.Gov, PubMed, Cochrane CENTRAL, SCOPUS, and Web of Science from their inception through 31 July 2021 for relevant studies. We included only controlled trials and ultimately seven trials were included in our meta-analysis.</p><p><strong>Participants: </strong>Inclusion criteria included women undergoing gynecological laparoscopic surgery.</p><p><strong>Intervention: </strong>The intervention of direct trocar insertion technique compared with Veress needle entry technique.</p><p><strong>Main outcome measures: </strong>We compared five different outcomes associated with the efficacy and complications of laparoscopic entry.</p><p><strong>Results: </strong>The pooled analysis showed that Veress needle entry was associated with a significant increase in the incidences of extraperitoneal insufflation (RR=0.177, 95% Cl (0.094 to 0.333), p<0.001), omental injury (RR=0.418, 95% Cl (0.195 to 0.896), p<0.001), failed entry (RR=0.173, 95% Cl (0.102 to 0.292), p<0.001), and trocar site infection (RR=0.404, 95% Cl (0.180 to 0.909), p<0.029). There was no significant difference between the two groups regarding the visceral injury (RR=0.562, 95% Cl (0.047 to 6.676), p<0.648).</p><p><strong>Conclusions: </strong>When excluding all data apart from gynecologic surgery, the Veress needle entry technique may have an increased incidence of some, but not all complications of laparoscopic entry. It may also have a higher incidence of failed entry compared with direct entry techniques. Care should be taken in extrapolating these general results to specific surgeon experience levels.</p><p><strong>Trial registration number: </strong>CRD42021273726.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/40/bmjsit-2021-000121.PMC9240888.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40637431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Debridement of diabetic foot ulcers: public health and clinical implications - a systematic review, meta-analysis, and meta-regression. 糖尿病足溃疡的清创:公共卫生和临床意义--系统回顾、荟萃分析和荟萃回归。
IF 2.1 Q2 SURGERY Pub Date : 2022-05-30 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000081
David Dayya, Owen O'Neill, Nusrat Habib, Joanna Moore, Kartik Iyer, Tania B Huedo-Medina

Background: Diabetic foot ulceration (DFU) has devastating complications and a lifetime occurrence of 15%-34%. Debridement of DFU is regarded as an intervention that accelerates ulcer healing and may reduce complications including amputations, infections, and poor quality of life (QoL), which have serious public health and clinical implications. A systematic review (SR) of SRs and of randomized controlled trials (RCTs) with meta-analyses (MAs) on debridement of DFU that synthesizes all human experimental evidence is warranted.

Objectives: Are debridement methods in DFU beneficial over other forms and standard gauze dressings (control condition) in these outcomes?

Study eligibility criteria: All SRs/MAs/RCTs comparing debridement methods for DFU with alternative methods of debridement and with control.

Data sources: Cochrane Wounds Group Specialized Register, Cochrane Central Register of Controlled Trials (Cochrane Library), Ovid MEDLINE, PubMed, EMBASE, EBSCO, CINAHL, and Web of Science.

Participants and interventions: Adults with type 1/2 diabetes with DFU and any debridement method compared with alternative debridement methods or control.

Main outcomes: Amputation rates, wound infections, QoL, proportion of ulcers healed, time to complete healing, ulcer recurrence, and treatment cost.

Study selection and analysis: Data extraction/synthesis by two independent reviewers pooled using a random-effects model with sensitivity analysis.

Results: 10 SRs were retrieved and reported qualitatively. Six SRs included MAs. This SR included 30 studies, with 2654 participants, using 19 debridement combinations. The debridement methods were compared with findings pooled into MAs. Meta-regression (MR) did not identify significant predictors/moderators of outcomes.

Limitations: The studies may have been under-powered. The inclusion/exclusion criteria varied and the increased risk of bias contributed to low-quality evidence.

Discussion/conclusion: Weak evidence exists that debridement methods are superior to other forms of debridement or control in DFU.

Implications: Researchers should follow standardized reporting guidelines (Consolidated Standards of Reporting Trials). Clinicians/investigators could use the findings from this SR/MA/MR in guiding patient-individualized decision making and designing future RCTs.

背景:糖尿病足溃疡(DFU)具有破坏性并发症,终生发病率为 15%-34%。对糖尿病足溃疡进行清创治疗被认为是一种干预措施,可加快溃疡愈合,减少截肢、感染和生活质量低下等并发症,对公共卫生和临床都有严重影响。因此,有必要就 DFU 的清创进行系统综述(SR)和随机对照试验(RCT),并进行荟萃分析(MA),以综合所有人类实验证据:研究资格标准:所有比较 DFU 清创方法与其他清创方法及对照组的 SR/MA/RCT:Cochrane Wounds Group Specialized Register、Cochrane Central Register of Controlled Trials (Cochrane Library)、Ovid MEDLINE、PubMed、EMBASE、EBSCO、CINAHL 和 Web of Science:主要结果:主要结果:截肢率、伤口感染、QoL、溃疡愈合比例、完全愈合时间、溃疡复发和治疗成本:数据提取/综合:由两名独立审稿人使用随机效应模型和敏感性分析进行汇总:结果:共检索到 10 篇 SR,并进行了定性报告。有 6 份研究报告纳入了 MA。本研究纳入了 30 项研究,共有 2654 人参与,使用了 19 种清创组合。对清创方法进行了比较,并将结果汇总到 MAs 中。元回归(Meta-Regression,MR)没有发现显著的结果预测因子/调节因子:局限性:研究可能未达到预期效果。讨论/结论:在 DFU 中,清创方法优于其他清创或控制方法的证据不足:研究人员应遵循标准化报告指南(试验报告综合标准)。临床医生/研究人员可利用该SR/MA/MR的研究结果来指导患者的个体化决策,并设计未来的RCT。
{"title":"Debridement of diabetic foot ulcers: public health and clinical implications - a systematic review, meta-analysis, and meta-regression.","authors":"David Dayya, Owen O'Neill, Nusrat Habib, Joanna Moore, Kartik Iyer, Tania B Huedo-Medina","doi":"10.1136/bmjsit-2021-000081","DOIUrl":"10.1136/bmjsit-2021-000081","url":null,"abstract":"<p><strong>Background: </strong>Diabetic foot ulceration (DFU) has devastating complications and a lifetime occurrence of 15%-34%. Debridement of DFU is regarded as an intervention that accelerates ulcer healing and may reduce complications including amputations, infections, and poor quality of life (QoL), which have serious public health and clinical implications. A systematic review (SR) of SRs and of randomized controlled trials (RCTs) with meta-analyses (MAs) on debridement of DFU that synthesizes all human experimental evidence is warranted.</p><p><strong>Objectives: </strong>Are debridement methods in DFU beneficial over other forms and standard gauze dressings (control condition) in these outcomes?</p><p><strong>Study eligibility criteria: </strong>All SRs/MAs/RCTs comparing debridement methods for DFU with alternative methods of debridement and with control.</p><p><strong>Data sources: </strong>Cochrane Wounds Group Specialized Register, Cochrane Central Register of Controlled Trials (Cochrane Library), Ovid MEDLINE, PubMed, EMBASE, EBSCO, CINAHL, and Web of Science.</p><p><strong>Participants and interventions: </strong>Adults with type 1/2 diabetes with DFU and any debridement method compared with alternative debridement methods or control.</p><p><strong>Main outcomes: </strong>Amputation rates, wound infections, QoL, proportion of ulcers healed, time to complete healing, ulcer recurrence, and treatment cost.</p><p><strong>Study selection and analysis: </strong>Data extraction/synthesis by two independent reviewers pooled using a random-effects model with sensitivity analysis.</p><p><strong>Results: </strong>10 SRs were retrieved and reported qualitatively. Six SRs included MAs. This SR included 30 studies, with 2654 participants, using 19 debridement combinations. The debridement methods were compared with findings pooled into MAs. Meta-regression (MR) did not identify significant predictors/moderators of outcomes.</p><p><strong>Limitations: </strong>The studies may have been under-powered. The inclusion/exclusion criteria varied and the increased risk of bias contributed to low-quality evidence.</p><p><strong>Discussion/conclusion: </strong>Weak evidence exists that debridement methods are superior to other forms of debridement or control in DFU.</p><p><strong>Implications: </strong>Researchers should follow standardized reporting guidelines (Consolidated Standards of Reporting Trials). Clinicians/investigators could use the findings from this SR/MA/MR in guiding patient-individualized decision making and designing future RCTs.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/db/bmjsit-2021-000081.PMC9152938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40026407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgeon experience of mixed reality headset technology during the COVID-19 pandemic: a multicenter international case series in orthopedic surgery COVID-19大流行期间混合现实头盔技术的外科医生经验:多中心国际骨科手术病例系列
Q2 Medicine Pub Date : 2022-05-01 DOI: 10.1136/bmjsit-2021-000127
T. Gregory, J. Gregory, Charles Dacheux, S. Hurst
INTRODUCTION There is interest in using reality technologies within the medical sphere and specific focus within orthopedic surgery. Mixed reality (MR) is a type of reality technology that allows for a digital image to be both superimposed and controlled by the user on top of their normal visual field. Using MR headsets, surgeons can access computerbased solutions in real time; manipulate threedimensional (3D) holograms of patient anatomy, surgical planning, or implant systems; and remotely interact with colleagues. All these functions are achieved without compromising sterility and have been demonstrated successfully. Despite these successes, there has been no significant investigation into its impact on surgeon experience. Evaluating the surgeon experience of MR will be of importance in understanding how it can best be deployed and further optimized for the benefit of patients. We report on surgeon experience following an international case series of orthopedic surgeries performed using MR headset technology during the COVID19 pandemic.
人们对在医疗领域和骨科手术中使用现实技术很感兴趣。混合现实(MR)是一种现实技术,它允许用户在其正常视野之上叠加和控制数字图像。使用磁共振头盔,外科医生可以实时访问基于计算机的解决方案;操作三维(3D)全息图的病人解剖,手术计划,或植入系统;并与同事远程互动。所有这些功能都是在不影响无菌的情况下实现的,并且已经成功地证明了这一点。尽管取得了这些成功,但还没有对其对外科医生经验的影响进行重大调查。评估外科医生的MR经验对于了解如何最好地部署和进一步优化患者的利益是很重要的。我们报告了在covid - 19大流行期间使用MR耳机技术进行骨科手术的国际病例系列后的外科医生经验。
{"title":"Surgeon experience of mixed reality headset technology during the COVID-19 pandemic: a multicenter international case series in orthopedic surgery","authors":"T. Gregory, J. Gregory, Charles Dacheux, S. Hurst","doi":"10.1136/bmjsit-2021-000127","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000127","url":null,"abstract":"INTRODUCTION There is interest in using reality technologies within the medical sphere and specific focus within orthopedic surgery. Mixed reality (MR) is a type of reality technology that allows for a digital image to be both superimposed and controlled by the user on top of their normal visual field. Using MR headsets, surgeons can access computerbased solutions in real time; manipulate threedimensional (3D) holograms of patient anatomy, surgical planning, or implant systems; and remotely interact with colleagues. All these functions are achieved without compromising sterility and have been demonstrated successfully. Despite these successes, there has been no significant investigation into its impact on surgeon experience. Evaluating the surgeon experience of MR will be of importance in understanding how it can best be deployed and further optimized for the benefit of patients. We report on surgeon experience following an international case series of orthopedic surgeries performed using MR headset technology during the COVID19 pandemic.","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47900913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
User-centered design and agile development of a novel mobile health application and clinician dashboard to support the collection and reporting of patient-reported outcomes for breast cancer care 以用户为中心的设计和敏捷开发新颖的移动健康应用程序和临床医生仪表板,以支持收集和报告患者报告的乳腺癌护理结果
Q2 Medicine Pub Date : 2022-04-01 DOI: 10.1136/bmjsit-2021-000119
E. Tsangaris, M. Edelen, Jessica J. Means, M. Gregorowitsch, Joanna O’Gorman, R. Pattanaik, L. Dominici, Michael Hassett, M. Witkowski, Kristen Schrieber, Elizabeth Frank, Martha Carnie, A. Pusic
Objectives There is a need for advancements in health information technology that will transform how patient-reported outcomes (PRO) data are collected, reported, and used in breast cancer care. The objective of this study was to develop an innovative and customizable platform, called imPROVE to support PRO uptake in breast cancer care. Design User-centered design and agile development were employed. Recurrent stakeholder meetings with experts in the field of breast cancer care, in-depth one-on-one qualitative interviews with a clinical sample of patients with breast cancer, and focus groups with Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer Advisory Group members, were used to elicit feedback for the design features and functions of a patient mobile application and clinician dashboard. Setting This study was conducted at two academic hospitals in the USA. Participants Participants included experts in the field of breast cancer care, value-based healthcare, and health information technology, a clinical sample of patients with breast cancer, and members of the DF/HCC Breast Cancer Advisory Group. Main outcome measures imPROVE incorporates the International Consortium for Health Outcomes Measurement (ICHOM) breast cancer standard outcome set as well as the complete BREAST-Q Breast Cancer Module. Results Feedback was elicited from eight stakeholder meetings (n=28 members), interviews with a clinical sample of patients (n=28), and two focus groups with members of the DF/HCC Breast Cancer Advisory Group (n=17 members in each focus group). Participant feedback led to the development of a patient mobile application consisting of five components (myCare, myStory, myResources, myCommunity, and myNotes) and a clinician dashboard that includes an overview table and individual patient profiles with data displays. Conclusions imPROVE has the potential to transform the way we deliver care to patients. Developed from best practices in user-centered design, agile development, and qualitative methods; imPROVE addresses the needs of multiple stakeholders, including patients, clinicians, healthcare administrators, and researchers.
目的需要健康信息技术的进步,以改变癌症治疗中患者报告结果(PRO)数据的收集、报告和使用方式。本研究的目的是开发一个创新和可定制的平台,称为imPROVE,以支持乳腺癌症护理中的PRO摄取。设计采用了以用户为中心的设计和敏捷开发。与乳腺癌症护理领域的专家定期举行利益相关者会议,对癌症患者临床样本进行深入的一对一定性访谈,并与Dana-Farber/哈佛癌症中心(DF/HCC)乳腺癌症咨询小组成员进行焦点小组讨论,用于引发对患者移动应用程序和临床医生仪表板的设计特征和功能的反馈。背景这项研究在美国两家学术医院进行。参与者包括乳腺癌症护理、价值医疗和健康信息技术领域的专家、癌症患者的临床样本以及DF/HCC癌症乳腺癌咨询小组的成员。主要结果测量imPROVE包含国际健康结果测量联合会(ICHOM)癌症乳腺癌标准结果集以及完整的BREST-Q癌症乳腺癌模块。结果从八次利益相关者会议(n=28名成员)、对患者临床样本的访谈(n=28)以及DF/HCC乳腺癌症咨询小组成员的两个焦点小组(每个焦点小组n=17名成员)中获得反馈。参与者的反馈导致开发了一个患者移动应用程序,该应用程序由五个组件(myCare、myStory、myResources、myCommunity和myNotes)和一个临床医生面板组成,其中包括一个概览表和带有数据显示的单个患者简档。结论imPROVE有可能改变我们为患者提供护理的方式。根据以用户为中心的设计、敏捷开发和定性方法的最佳实践开发;imPROVE解决了多个利益相关者的需求,包括患者、临床医生、医疗保健管理人员和研究人员。
{"title":"User-centered design and agile development of a novel mobile health application and clinician dashboard to support the collection and reporting of patient-reported outcomes for breast cancer care","authors":"E. Tsangaris, M. Edelen, Jessica J. Means, M. Gregorowitsch, Joanna O’Gorman, R. Pattanaik, L. Dominici, Michael Hassett, M. Witkowski, Kristen Schrieber, Elizabeth Frank, Martha Carnie, A. Pusic","doi":"10.1136/bmjsit-2021-000119","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000119","url":null,"abstract":"Objectives There is a need for advancements in health information technology that will transform how patient-reported outcomes (PRO) data are collected, reported, and used in breast cancer care. The objective of this study was to develop an innovative and customizable platform, called imPROVE to support PRO uptake in breast cancer care. Design User-centered design and agile development were employed. Recurrent stakeholder meetings with experts in the field of breast cancer care, in-depth one-on-one qualitative interviews with a clinical sample of patients with breast cancer, and focus groups with Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer Advisory Group members, were used to elicit feedback for the design features and functions of a patient mobile application and clinician dashboard. Setting This study was conducted at two academic hospitals in the USA. Participants Participants included experts in the field of breast cancer care, value-based healthcare, and health information technology, a clinical sample of patients with breast cancer, and members of the DF/HCC Breast Cancer Advisory Group. Main outcome measures imPROVE incorporates the International Consortium for Health Outcomes Measurement (ICHOM) breast cancer standard outcome set as well as the complete BREAST-Q Breast Cancer Module. Results Feedback was elicited from eight stakeholder meetings (n=28 members), interviews with a clinical sample of patients (n=28), and two focus groups with members of the DF/HCC Breast Cancer Advisory Group (n=17 members in each focus group). Participant feedback led to the development of a patient mobile application consisting of five components (myCare, myStory, myResources, myCommunity, and myNotes) and a clinician dashboard that includes an overview table and individual patient profiles with data displays. Conclusions imPROVE has the potential to transform the way we deliver care to patients. Developed from best practices in user-centered design, agile development, and qualitative methods; imPROVE addresses the needs of multiple stakeholders, including patients, clinicians, healthcare administrators, and researchers.","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44760434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
First in-human trial and prospective case series of an articulated laparoscopic camera system in minimally invasive surgery in gynecology: an IDEAL stage 1 and 2a study. 妇科微创手术中关节式腹腔镜相机系统的首次人体试验和前瞻性病例系列:一项IDEAL 1期和2a期研究。
Q2 Medicine Pub Date : 2022-03-04 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000117
Tong Yow Ng, Siew Fei Ngu, Tat Yan Deyoung Kam, Sai Yan Ng, Ping Lai Benny Lo

Objectives: Precision Robotics' Sirius Robotic Flexible Endoscopic System is a new, fully integrated, compact three-dimensional laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction. This IDEAL Stage 1 and 2a study assessed its safety, reliability and potential efficacy particularly for single incision laparoscopic surgery and vaginal natural orifice transluminal endoscopic surgery.

Design: Prospective single-institution, single-surgeon study.

Setting: The study was conducted in a multispecialty hospital.

Participants: Women aged 18-70 years scheduled for gynecological laparoscopic surgery were invited to participate. An information sheet and consent was available for the women and an informed consent was obtained. Thirteen participants completed this study.

Interventions: The laparoscopic procedures were done in the usual manner. The only difference was the Sirius System was used in place of the conventional laparoscope. All other procedures and instruments remained the same.

Main outcome measures: Primary outcome was the proportion of women who successfully completed the intended procedure using the Sirius System without conversion to another camera system, camera users and surgeon's view and experience, and iterations and modifications to the system. Secondary outcomes were the incidence of intraoperative and postoperative complications during the first 6 weeks following surgery, and duration of surgery.

Results: 85% (11/13) of women had their procedure completed successfully using the Sirius System. Two women required immediate conversion to the conventional laparoscope due to technical issues. There were no intraoperative complications. Users agreed that the improved field of view was beneficial for laparoscopic surgery. Iterative improvements were made in the imaging quality, user interface and manufacturing quality.

Conclusions: Sirius System has early indications for safety and efficacy for intermediate and major minimally invasive laparoscopic procedures in gynecology. Further studies are needed to confirm it can replace a conventional laparoscope in the surgical workflow.

Trial registration number: NCT05048407.

目的:精密机器人公司的Sirius机器人柔性内窥镜系统是一种全新的、完全集成的、紧凑的三维腹腔镜相机系统,具有一次性使用的柔性尖端,可以改变其观察方向。这项IDEAL 1期和2a期研究评估了其安全性、可靠性和潜在疗效,特别是单切口腹腔镜手术和阴道自然孔腔内内镜手术。设计:前瞻性单机构、单外科医生研究。环境:本研究在一家多专科医院进行。对象:年龄在18-70岁,计划进行妇科腹腔镜手术的女性。向妇女提供了一份信息表和同意书,并取得了知情同意。13名参与者完成了这项研究。干预措施:腹腔镜手术按常规方式进行。唯一的区别是用天狼星系统代替了传统的腹腔镜。所有其他程序和工具保持不变。主要结果测量:主要结果是使用Sirius系统成功完成预期手术的女性比例,而无需转换到另一个相机系统,相机用户和外科医生的观点和经验,以及对系统的迭代和修改。次要结局是术后前6周术中和术后并发症的发生率以及手术持续时间。结果:85%(11/13)的女性使用天狼星系统成功完成了手术。由于技术问题,两名妇女需要立即转换到传统腹腔镜。无术中并发症。用户一致认为,视野的改善有利于腹腔镜手术。在成像质量、用户界面和制造质量方面进行了迭代改进。结论:Sirius系统在妇科中、大型微创腹腔镜手术中具有安全性和有效性的早期适应症。需要进一步的研究来证实它可以在手术流程中取代传统的腹腔镜。试验注册号:NCT05048407。
{"title":"First in-human trial and prospective case series of an articulated laparoscopic camera system in minimally invasive surgery in gynecology: an IDEAL stage 1 and 2a study.","authors":"Tong Yow Ng,&nbsp;Siew Fei Ngu,&nbsp;Tat Yan Deyoung Kam,&nbsp;Sai Yan Ng,&nbsp;Ping Lai Benny Lo","doi":"10.1136/bmjsit-2021-000117","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000117","url":null,"abstract":"<p><strong>Objectives: </strong>Precision Robotics' Sirius Robotic Flexible Endoscopic System is a new, fully integrated, compact three-dimensional laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction. This IDEAL Stage 1 and 2a study assessed its safety, reliability and potential efficacy particularly for single incision laparoscopic surgery and vaginal natural orifice transluminal endoscopic surgery.</p><p><strong>Design: </strong>Prospective single-institution, single-surgeon study.</p><p><strong>Setting: </strong>The study was conducted in a multispecialty hospital.</p><p><strong>Participants: </strong>Women aged 18-70 years scheduled for gynecological laparoscopic surgery were invited to participate. An information sheet and consent was available for the women and an informed consent was obtained. Thirteen participants completed this study.</p><p><strong>Interventions: </strong>The laparoscopic procedures were done in the usual manner. The only difference was the Sirius System was used in place of the conventional laparoscope. All other procedures and instruments remained the same.</p><p><strong>Main outcome measures: </strong>Primary outcome was the proportion of women who successfully completed the intended procedure using the Sirius System without conversion to another camera system, camera users and surgeon's view and experience, and iterations and modifications to the system. Secondary outcomes were the incidence of intraoperative and postoperative complications during the first 6 weeks following surgery, and duration of surgery.</p><p><strong>Results: </strong>85% (11/13) of women had their procedure completed successfully using the Sirius System. Two women required immediate conversion to the conventional laparoscope due to technical issues. There were no intraoperative complications. Users agreed that the improved field of view was beneficial for laparoscopic surgery. Iterative improvements were made in the imaging quality, user interface and manufacturing quality.</p><p><strong>Conclusions: </strong>Sirius System has early indications for safety and efficacy for intermediate and major minimally invasive laparoscopic procedures in gynecology. Further studies are needed to confirm it can replace a conventional laparoscope in the surgical workflow.</p><p><strong>Trial registration number: </strong>NCT05048407.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/f3/bmjsit-2021-000117.PMC8900025.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40314584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development stage of novel digital health interventions for postoperative monitoring: protocol of a systematic review. 用于术后监测的新型数字健康干预措施的发展阶段:系统评价方案。
Q2 Medicine Pub Date : 2022-03-04 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000104
Kenneth A McLean, Stephen R Knight, Thomas M Diehl, Syed Nabeel Zafar, Matt Bouamrane, Ewen M Harrison

Introduction: The postoperative period represents a time where patients are at a high-risk of morbidity, which warrants effective surveillance. While digital health interventions (DHIs) for postoperative monitoring are promising, a coordinated, standardized and evidence-based approach regarding their implementation and evaluation is currently lacking. This study aimed to identify DHIs implemented and evaluated in postoperative care to highlight research gaps and assess the readiness for routine implementation.

Methods: A systematic review will be conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify studies describing the implementation and evaluation of DHIs for postoperative monitoring published since 2000 (PROSPERO ID: CRD42021264289). This will encompass the Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Web of Science and ClinicalTrials.gov databases, and manual search of bibliographies for relevant studies and gray literature. Methodological reporting quality will be evaluated using the Idea, Development, Exploration, Assessment and Long-term Follow-up (IDEAL) reporting guideline relevant to the IDEAL stage of the study, and risk of bias will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. Data will be extracted according to the WHO framework for monitoring and evaluating DHIs, and a narrative synthesis will be performed.

Discussion: This review will assess the readiness for implementation of DHIs for routine postoperative monitoring and will include studies describing best practice from service changes already being piloted out of necessity during the COVID-19 pandemic. This will identify interventions with sufficient evidence to progress to the next IDEAL stage, and promote standardized and comprehensive evaluation of future implementational studies.

导言:术后是患者发病的高危期,需要进行有效的监测。虽然用于术后监测的数字健康干预措施(DHIs)很有前景,但目前缺乏一种协调、标准化和基于证据的方法来实施和评估。本研究旨在确定DHIs在术后护理中的实施和评估,以突出研究差距并评估常规实施的准备情况。方法:根据系统评价和荟萃分析指南的首选报告项目进行系统评价,以确定自2000年以来发表的描述DHIs用于术后监测的实施和评估的研究(PROSPERO ID: CRD42021264289)。这将包括Embase、护理和相关健康文献累积索引、Cochrane图书馆、Web of Science和ClinicalTrials.gov数据库,以及人工搜索相关研究和灰色文献的书目。方法学报告的质量将使用与研究的理想阶段相关的构想、发展、探索、评估和长期随访(IDEAL)报告指南进行评估,偏倚风险将使用建议、评估、发展和评估分级(GRADE)框架进行评估。将根据世卫组织监测和评价卫生保健的框架提取数据,并进行叙述综合。讨论:本次审查将评估实施DHIs用于常规术后监测的准备情况,并将包括描述在2019冠状病毒病大流行期间出于必要已经试点的服务变革的最佳实践的研究。这将确定有足够证据的干预措施,以进入理想的下一个阶段,并促进对未来实施研究的标准化和全面评价。
{"title":"Development stage of novel digital health interventions for postoperative monitoring: protocol of a systematic review.","authors":"Kenneth A McLean,&nbsp;Stephen R Knight,&nbsp;Thomas M Diehl,&nbsp;Syed Nabeel Zafar,&nbsp;Matt Bouamrane,&nbsp;Ewen M Harrison","doi":"10.1136/bmjsit-2021-000104","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000104","url":null,"abstract":"<p><strong>Introduction: </strong>The postoperative period represents a time where patients are at a high-risk of morbidity, which warrants effective surveillance. While digital health interventions (DHIs) for postoperative monitoring are promising, a coordinated, standardized and evidence-based approach regarding their implementation and evaluation is currently lacking. This study aimed to identify DHIs implemented and evaluated in postoperative care to highlight research gaps and assess the readiness for routine implementation.</p><p><strong>Methods: </strong>A systematic review will be conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify studies describing the implementation and evaluation of DHIs for postoperative monitoring published since 2000 (PROSPERO ID: CRD42021264289). This will encompass the Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Web of Science and ClinicalTrials.gov databases, and manual search of bibliographies for relevant studies and gray literature. Methodological reporting quality will be evaluated using the Idea, Development, Exploration, Assessment and Long-term Follow-up (IDEAL) reporting guideline relevant to the IDEAL stage of the study, and risk of bias will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. Data will be extracted according to the WHO framework for monitoring and evaluating DHIs, and a narrative synthesis will be performed.</p><p><strong>Discussion: </strong>This review will assess the readiness for implementation of DHIs for routine postoperative monitoring and will include studies describing best practice from service changes already being piloted out of necessity during the COVID-19 pandemic. This will identify interventions with sufficient evidence to progress to the next IDEAL stage, and promote standardized and comprehensive evaluation of future implementational studies.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40314586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Transesophageal echocardiography and risk of respiratory failure in patients who had ischemic stroke or transient ischemic attack: an IDEAL phase 4 study. 经食管超声心动图与缺血性卒中或短暂性缺血性发作患者呼吸衰竭的风险:一项IDEAL 4期研究
Q2 Medicine Pub Date : 2022-02-07 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000116
Samuel S Bruce, Babak B Navi, Cenai Zhang, Jiwon Kim, Richard B Devereux, Edward J Schenck, Art Sedrakyan, Iván Díaz, Hooman Kamel

Objective: Transesophageal echocardiography (TEE) is sometimes used to search for cardioembolic sources after ischemic stroke or transient ischemic attack (TIA). TEE visualizes some sources better than transthoracic echocardiography, but TEE is invasive and may cause aspiration. Few data exist on the risk of respiratory complications after TEE in patients who had stroke or TIA. Our objective was to determine whether TEE was associated with increased risk of respiratory failure in patients who had ischemic stroke or TIA.

Design: This is a retrospective cohort study using administrative data from inpatient and outpatient insurance claims collected by the US federal government's Centers for Medicare and Medicaid Services.

Setting: Hospitals and outpatient clinics throughout the USA.

Participants: 99 081 patients ≥65 years old hospitalized for out-of-hospital ischemic stroke or TIA, defined by validated International Classification of Disease-9/10 diagnosis codes and present-on-admission codes, using claims data from 2008 to 2018 in a random 5% sample of Medicare beneficiaries.

Main outcome measures: Acute respiratory failure, defined as endotracheal intubation and/or mechanical ventilation, starting on the first day after admission through 28 days afterward.

Results: Of 99 081 patients included in this analysis, 73 733 (74.4%) had an ischemic stroke and 25 348 (25.6%) a TIA. TEE was performed in 4677 (4.7%) patients and intubation and/or mechanical ventilation in 1403 (1.4%) patients. The 28-day cumulative risk of respiratory failure after TEE (1.4%; 95% CI 0.8% to 2.7%) was similar to that seen in those without TEE (1.4%; 95% CI 1.4% to 1.5%) (p=0.84). After adjustment for age, sex, race, Charlson comorbidities, diagnosis of stroke versus TIA, intravenous thrombolysis, and mechanical thrombectomy, TEE was not associated with an increased risk of respiratory failure (HR, 0.9; 95% CI 0.6 to 1.2).

Conclusions: In a cohort of older patients who had ischemic stroke or TIA, TEE was not associated with an increased risk of subsequent respiratory failure.

目的:经食管超声心动图(TEE)有时用于寻找缺血性卒中或短暂性脑缺血发作(TIA)后的心脏栓塞源。TEE比经胸超声心动图能更好地显示某些来源,但TEE是侵入性的,可能导致误吸。很少有关于卒中或TIA患者TEE后呼吸系统并发症风险的数据。我们的目的是确定TEE是否与缺血性卒中或TIA患者呼吸衰竭风险增加有关。设计:这是一项回顾性队列研究,使用美国联邦政府医疗保险和医疗补助服务中心收集的住院和门诊保险索赔的行政数据。地点:美国各地的医院和门诊诊所。参与者:99081例≥65岁院外缺血性卒中或TIA住院患者,由经过验证的国际疾病分类9/10诊断代码和入院时代码定义,使用2008年至2018年的索赔数据,随机抽取5%的医疗保险受益人样本。主要结局指标:急性呼吸衰竭,定义为气管插管和/或机械通气,从入院后第一天开始至28天后。结果:纳入本分析的99 081例患者中,73 733例(74.4%)发生缺血性卒中,25 348例(25.6%)发生TIA。4677例(4.7%)患者行TEE, 1403例(1.4%)患者行插管和/或机械通气。TEE术后28天累积呼吸衰竭风险(1.4%;95% CI 0.8% - 2.7%)与未TEE患者相似(1.4%;95% CI 1.4% ~ 1.5%) (p=0.84)。在调整了年龄、性别、种族、Charlson合并症、卒中与TIA的诊断、静脉溶栓和机械取栓等因素后,TEE与呼吸衰竭风险增加无关(HR, 0.9;95% CI 0.6 - 1.2)。结论:在缺血性卒中或TIA的老年患者队列中,TEE与随后的呼吸衰竭风险增加无关。
{"title":"Transesophageal echocardiography and risk of respiratory failure in patients who had ischemic stroke or transient ischemic attack: an IDEAL phase 4 study.","authors":"Samuel S Bruce,&nbsp;Babak B Navi,&nbsp;Cenai Zhang,&nbsp;Jiwon Kim,&nbsp;Richard B Devereux,&nbsp;Edward J Schenck,&nbsp;Art Sedrakyan,&nbsp;Iván Díaz,&nbsp;Hooman Kamel","doi":"10.1136/bmjsit-2021-000116","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000116","url":null,"abstract":"<p><strong>Objective: </strong>Transesophageal echocardiography (TEE) is sometimes used to search for cardioembolic sources after ischemic stroke or transient ischemic attack (TIA). TEE visualizes some sources better than transthoracic echocardiography, but TEE is invasive and may cause aspiration. Few data exist on the risk of respiratory complications after TEE in patients who had stroke or TIA. Our objective was to determine whether TEE was associated with increased risk of respiratory failure in patients who had ischemic stroke or TIA.</p><p><strong>Design: </strong>This is a retrospective cohort study using administrative data from inpatient and outpatient insurance claims collected by the US federal government's Centers for Medicare and Medicaid Services.</p><p><strong>Setting: </strong>Hospitals and outpatient clinics throughout the USA.</p><p><strong>Participants: </strong>99 081 patients ≥65 years old hospitalized for out-of-hospital ischemic stroke or TIA, defined by validated International Classification of Disease-9/10 diagnosis codes and present-on-admission codes, using claims data from 2008 to 2018 in a random 5% sample of Medicare beneficiaries.</p><p><strong>Main outcome measures: </strong>Acute respiratory failure, defined as endotracheal intubation and/or mechanical ventilation, starting on the first day after admission through 28 days afterward.</p><p><strong>Results: </strong>Of 99 081 patients included in this analysis, 73 733 (74.4%) had an ischemic stroke and 25 348 (25.6%) a TIA. TEE was performed in 4677 (4.7%) patients and intubation and/or mechanical ventilation in 1403 (1.4%) patients. The 28-day cumulative risk of respiratory failure after TEE (1.4%; 95% CI 0.8% to 2.7%) was similar to that seen in those without TEE (1.4%; 95% CI 1.4% to 1.5%) (p=0.84). After adjustment for age, sex, race, Charlson comorbidities, diagnosis of stroke versus TIA, intravenous thrombolysis, and mechanical thrombectomy, TEE was not associated with an increased risk of respiratory failure (HR, 0.9; 95% CI 0.6 to 1.2).</p><p><strong>Conclusions: </strong>In a cohort of older patients who had ischemic stroke or TIA, TEE was not associated with an increased risk of subsequent respiratory failure.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/18/bmjsit-2021-000116.PMC8823208.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39637358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
IDEAL approach to the evaluation of machine learning technology in epilepsy surgery: protocol for the MAST trial. 评估癫痫手术中机器学习技术的 IDEAL 方法:MAST 试验协议。
IF 2.1 Q2 SURGERY Pub Date : 2022-01-27 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000109
Aswin Chari, Sophie Adler, Konrad Wagstyl, Kiran Seunarine, Hani Marcus, Torsten Baldeweg, Martin Tisdall

Epilepsy and epilepsy surgery lend themselves well to the application of machine learning (ML) and artificial intelligence (AI) technologies. This is evidenced by the plethora of tools developed for applications such as seizure detection and analysis of imaging and electrophysiological data. However, few of these tools have been directly used to guide patient management. In recent years, the Idea, Development, Exploration, Assessment, Long-Term Follow-Up (IDEAL) collaboration has formalised stages for the evaluation of surgical innovation and medical devices, and, in many ways, this pragmatic framework is also applicable to ML/AI technology, balancing innovation and safety. In this protocol paper, we outline the preclinical (IDEAL stage 0) evaluation and the protocol for a prospective (IDEAL stage 1/2a) study to evaluate the utility of an ML lesion detection algorithm designed to detect focal cortical dysplasia from structural MRI, as an adjunct in the planning of stereoelectroencephalography trajectories in children undergoing intracranial evaluation for drug-resistant epilepsy.

癫痫和癫痫手术非常适合应用机器学习(ML)和人工智能(AI)技术。为癫痫发作检测以及成像和电生理数据分析等应用而开发的大量工具就证明了这一点。然而,这些工具很少被直接用于指导患者管理。近年来,"构思、开发、探索、评估、长期跟踪"(IDEAL)合作正式确定了手术创新和医疗设备的评估阶段,在很多方面,这一务实的框架也适用于 ML/AI 技术,在创新和安全之间取得平衡。在本协议文件中,我们概述了临床前(IDEAL 第 0 阶段)评估和前瞻性(IDEAL 第 1/2a 阶段)研究的协议,该研究旨在评估 ML 病灶检测算法的实用性,该算法旨在从结构性 MRI 中检测局灶性皮质发育不良,作为对接受耐药性癫痫颅内评估的儿童进行立体脑电图轨迹规划的辅助手段。
{"title":"IDEAL approach to the evaluation of machine learning technology in epilepsy surgery: protocol for the MAST trial.","authors":"Aswin Chari, Sophie Adler, Konrad Wagstyl, Kiran Seunarine, Hani Marcus, Torsten Baldeweg, Martin Tisdall","doi":"10.1136/bmjsit-2021-000109","DOIUrl":"10.1136/bmjsit-2021-000109","url":null,"abstract":"<p><p>Epilepsy and epilepsy surgery lend themselves well to the application of machine learning (ML) and artificial intelligence (AI) technologies. This is evidenced by the plethora of tools developed for applications such as seizure detection and analysis of imaging and electrophysiological data. However, few of these tools have been directly used to guide patient management. In recent years, the Idea, Development, Exploration, Assessment, Long-Term Follow-Up (IDEAL) collaboration has formalised stages for the evaluation of surgical innovation and medical devices, and, in many ways, this pragmatic framework is also applicable to ML/AI technology, balancing innovation and safety. In this protocol paper, we outline the preclinical (IDEAL stage 0) evaluation and the protocol for a prospective (IDEAL stage 1/2a) study to evaluate the utility of an ML lesion detection algorithm designed to detect focal cortical dysplasia from structural MRI, as an adjunct in the planning of stereoelectroencephalography trajectories in children undergoing intracranial evaluation for drug-resistant epilepsy.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/fb/bmjsit-2021-000109.PMC8796270.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39763963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of radiation exposure and clinical outcomes between transradial and transfemoral diagnostic cerebral approaches: a retrospective study. 经桡动脉和经股动脉诊断脑部方法的辐射量和临床结果比较:一项回顾性研究。
Q2 Medicine Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.1136/bmjsit-2021-000110
Curtis Amankwah, Lauren Lombardo, John Rutledge, Ahsan Sattar, Bree Chancellor, Dorothea Altschul

Objective: To identify and compare patient and procedural variables that are associated with a high radiation dose exposure and worse clinical outcomes between transradial arterial (TRA) and transfemoral arterial (TFA) approaches.

Design: This was a retrospective analysis.

Setting: A community hospital during the initial phase of adopting a TRA-first approach.

Participants: A resultant 215 subjects who only underwent diagnostic cerebral angiograms (DCA) after excluding all therapeutic procedures and patients under 18 years.

Interventions: Only DCA from 1 May 2018 to 31 January 2021.

Main outcome measures: We compared radiation exposure parameters (total fluoroscopy time (FT), total radiation dose (TD) and dose area product (DAP), number of vessels injected and Patient-Reported Global Health Physical and Mental Outcome Scores (PROGHS) at 30 days postprocedure between groups.

Results: FT was significantly greater in TRA compared with TFA (p<0.001). In addition, TRA had a significantly higher TD (p=0.002) and DAP (p=0.005) when compared with TFA. Analysis of only 6-vessel DCAs also showed that TRA had a significantly higher FT, DAP and TD in comparison to TFA. Despite observing a longer FT in TRA, results showed fewer vessels injected and a notably lower success rate in acquiring a 6-vessel DCA using the TRA. Further analysis of the effect of vessel number on FT using general linear models showed that with every increase of one vessel, the FT increases by 2.2 min for TRA (p<0.001; 95% CI 1.03 to 3.36) and by 1.3 min for TFA (p<0.001; 95% CI 0.72 to 1.83). There was no significant difference between groups in PROGHS mental and physical t-scores at 30 days postprocedure, even though our cohort showed a significantly greater percentage of TRA procedures done in the outpatient setting.

Conclusions: Adopting a TRA first approach for DCAs may be initially associated with a higher radiation dose for the patient. Better strategies and devices are needed to mitigate this effect.

目的确定并比较经桡动脉(TRA)和经股动脉(TFA)方法中与高辐射剂量暴露和较差临床结果相关的患者和手术变量:设计:这是一项回顾性分析:环境: 一家社区医院,在采用 TRA 优先方法的初始阶段:在排除所有治疗程序和 18 岁以下患者后,215 名受试者仅接受了诊断性脑血管造影(DCA):主要结果测量:我们比较了各组间的辐射暴露参数(总透视时间(FT)、总辐射剂量(TD)和剂量面积乘积(DAP)、注射血管数量以及术后30天患者报告的全球健康身心结果评分(PROGHS):结果:与 TFA 相比,TRA 的 FT 明显更高(p结论:采用 TRA 为先的方法进行大动脉造影术,可大大提高手术的成功率:在 DCA 中首先采用 TRA 方法,最初可能会给患者带来较高的辐射剂量。需要更好的策略和设备来减轻这种影响。
{"title":"Comparison of radiation exposure and clinical outcomes between transradial and transfemoral diagnostic cerebral approaches: a retrospective study.","authors":"Curtis Amankwah, Lauren Lombardo, John Rutledge, Ahsan Sattar, Bree Chancellor, Dorothea Altschul","doi":"10.1136/bmjsit-2021-000110","DOIUrl":"10.1136/bmjsit-2021-000110","url":null,"abstract":"<p><strong>Objective: </strong>To identify and compare patient and procedural variables that are associated with a high radiation dose exposure and worse clinical outcomes between transradial arterial (TRA) and transfemoral arterial (TFA) approaches.</p><p><strong>Design: </strong>This was a retrospective analysis.</p><p><strong>Setting: </strong>A community hospital during the initial phase of adopting a TRA-first approach.</p><p><strong>Participants: </strong>A resultant 215 subjects who only underwent diagnostic cerebral angiograms (DCA) after excluding all therapeutic procedures and patients under 18 years.</p><p><strong>Interventions: </strong>Only DCA from 1 May 2018 to 31 January 2021.</p><p><strong>Main outcome measures: </strong>We compared radiation exposure parameters (total fluoroscopy time (FT), total radiation dose (TD) and dose area product (DAP), number of vessels injected and Patient-Reported Global Health Physical and Mental Outcome Scores (PROGHS) at 30 days postprocedure between groups.</p><p><strong>Results: </strong>FT was significantly greater in TRA compared with TFA (p<0.001). In addition, TRA had a significantly higher TD (p=0.002) and DAP (p=0.005) when compared with TFA. Analysis of only 6-vessel DCAs also showed that TRA had a significantly higher FT, DAP and TD in comparison to TFA. Despite observing a longer FT in TRA, results showed fewer vessels injected and a notably lower success rate in acquiring a 6-vessel DCA using the TRA. Further analysis of the effect of vessel number on FT using general linear models showed that with every increase of one vessel, the FT increases by 2.2 min for TRA (p<0.001; 95% CI 1.03 to 3.36) and by 1.3 min for TFA (p<0.001; 95% CI 0.72 to 1.83). There was no significant difference between groups in PROGHS mental and physical t-scores at 30 days postprocedure, even though our cohort showed a significantly greater percentage of TRA procedures done in the outpatient setting.</p><p><strong>Conclusions: </strong>Adopting a TRA first approach for DCAs may be initially associated with a higher radiation dose for the patient. Better strategies and devices are needed to mitigate this effect.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1b/d5/bmjsit-2021-000110.PMC8785198.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39895485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMJ Surgery Interventions Health Technologies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1